1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association;2013.
2. Goldman MJ. Kleptomania: making sense of the nonsensical. Am J Psychiatry. 1991; 148:986–996.
Article
3. Grant JE, Kim SW. Clinical characteristics and associated psychopathology of 22 patients with kleptomania. Compr Psychiatry. 2002; 43:378–384.
Article
4. Koran LM, Aboujaoude EN, Gamel NN. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J Clin Psychiatry. 2007; 68:422–427.
5. Grant JE, Kim SW, Odlaug BL. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biol Psychiatry. 2009; 65:600–606.
Article
6. Grant JE. Understanding and treating kleptomania: new models and new treatments. Isr J Psychiatry Relat Sci. 2006; 43:81–87.
7. Grant JE, Potenza MN. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry. 2004; 16:27–34.
Article
8. Grant JE, Odlaug BL. [Kleptomania: clinical characteristics and treatment]. Rev Bras Psiquiatr. 2008; 30:Supple 1. S11–S15.
9. Grant JE, Odlaug BL, Davis AA, Kim SW. Legal consequences of kleptomania. Psychiatr Q. 2009; 80:251–259.
Article
10. Presta S, Marazziti D, Dell'Osso L, Pfanner C, Pallanti S, Cassano GB. Kleptomania: clinical features and comorbidity in an Italian sample. Compr Psychiatry. 2002; 43:7–12.
Article
11. Fishbain DA. Kleptomania as risk-taking behavior in response to depression. Am J Psychother. 1987; 41:598–603.
Article
12. McElroy SL, Pope HG Jr, Hudson JI, Keck PE Jr, White KL. Kleptomania: a report of 20 cases. Am J Psychiatry. 1991; 148:652–657.
Article